Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group IND.221 -- A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin -- was centrally activated on August 24, 2015.

The primary Objective of the trial is to confirm the recommended phase II dose (RP2D) of single agent IPH2201 in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin.

Secondary objectives include to:
  • Characterize the pharmacokinetics of IPH2201 when administered as a single agent;
  • Assess the pharmacodynamic effects of single agent IPH2201;
  • Assess the safety and toxicity profile of single agent IPH2201;
  • Explore the efficacy of IPH2201 in platinum resistant or sensitive HGSC; and,
  • Characterize the immunogenicity of IPH2201 when administered as a single agent.